Erratum: Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments (Cancer Chemother Pharmacol (2013) 72 (369-378) DOI 10.1007/s00280-013-2206-x);Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments

Cancer Chemotherapy and Pharmacology

Volumn 72, Issue 2, 2013, Pages 369-378

  Pauley, Jennifer L ^a   Panetta, John C ^a,b   Crews, Kristine R ^a,b   Pei, Deqing ^a   Cheng, Cheng ^a   McCormick, John ^a   Howard, Scott C ^a,b   Sandlund, John T ^a,b   Jeha, Sima ^a,b   Ribeiro, Raul ^a,b   Rubnitz, Jeffrey ^a,b   Pui, Ching Hon ^a,b   Evans, William E ^a,b   Relling, Mary V ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Acute lymphoblastic leukemia; Individualized therapy; Methotrexate; Pharmacokinetics

Indexed keywords

BICARBONATE; FOLINIC ACID; METHOTREXATE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER PATIENT; CONTROLLED STUDY; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG EXCRETION; DRUG MEGADOSE; FEASIBILITY STUDY; GASTROINTESTINAL TOXICITY; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; STEADY STATE;

EID: 84880916562     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2325-4     Document Type: Erratum

References (42)

1. Pui CH, Campana D, Pei D, Bowman WP, Sandlund JT, Kaste SC, Ribeiro RC, Rubnitz JE, Raimondi SC, Onciu M, Coustan-Smith E, Kun LE, Jeha S, Cheng C, Howard SC, Simmons V, Bayles A, Metzger ML, Boyett JM, Leung W, Handgretinger R, Downing JR, Evans WE, Relling MV (2009) Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 360:2730-2741
2. Pui CH, Pei D, Sandlund JT, Ribeiro RC, Rubnitz JE, Raimondi SC, Onciu M, Campana D, Kun LE, Jeha S, Cheng C, Howard SC, Metzger ML, Bhojwani D, Downing JR, Evans WE, Relling MV (2010) Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia 24:371-382
3. Conter V, Arico M, Basso G, Biondi A, Barisone E, Messina C, Parasole R, De Rossi G, Locatelli F, Pession A, Santoro N, Micalizzi C, Citterio M, Rizzari C, Silvestri D, Rondelli R, Lo Nigro L, Ziino O, Testi AM, Masera G, Valsecchi MG (2010) Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia. Leukemia 24:255-264
4. Moricke A, Zimmermann M, Reiter A, Henze G, Schrauder A, Gadner H, Ludwig WD, Ritter J, Harbott J, Mann G, Klingebiel T, Zintl F, Niemeyer C, Kremens B, Niggli F, Niethammer D, Welte K, Stanulla M, Odenwald E, Riehm H, Schrappe M (2010) Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia 24:265-284
5. Gaynon PS, Angiolillo AL, Carroll WL, Nachman JB, Trigg ME, Sather HN, Hunger SP, Devidas M (2010) Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: a children's oncology group report. Leukemia 24:285-297
6. Reiter A, Schrappe M, Ludwig WD, Hiddemann W, Sauter S, Henze G, Zimmermann M, Lampert F, Havers W, Niethammer D et al (1994) Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 84:3122-3133 (Pubitemid 24328106)
7. Chauvenet AR, Martin PL, Devidas M, Linda SB, Bell BA, Kurtzberg J, Pullen J, Pettenati MJ, Carroll AJ, Shuster JJ, Camitta B (2007) Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from children's oncology group study P9201. Blood 110:1105-1111 (Pubitemid 47281404)
8. Silverman LB, Gelber RD, Dalton VK, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA, Arkin S, Declerck L, Cohen HJ, Sallan SE (2001) Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 97:1211-1218 (Pubitemid 32183741)
9. Clarke M, Gaynon P, Hann I, Harrison G, Masera G, Peto R, Richards S (2003) CNS-directed therapy for childhood acute lymphoblastic leukemia: childhood ALL Collaborative Group overview of 43 randomized trials. J Clin Oncol 21:1798-1809 (Pubitemid 46646217)
10. Galpin AJ, Schuetz JD, Masson E, Yanishevski Y, Synold TW, Barredo JC, Pui CH, Relling MV, Evans WE (1997) Differences in folylpolyglutamate synthetase and dihydrofolate reductase expression in human B-lineage versus T-lineage leukemic lymphoblasts: mechanisms for lineage differences in methotrexate polyglutamylation and cytotoxicity. Mol Pharmacol 52:155-163 (Pubitemid 27318631)
11. Pui CH, Sallan S, Relling MV, Masera G, Evans WE (2001) International childhood acute lymphoblastic leukemia workshop: Sausalito, CA, 30 Nov-1 Dec 2000. Leukemia 15: 707-15
12. Asselin BL, Devidas M, Wang C, Pullen J, Borowitz MJ, Hutchison R, Lipshultz SE, Camitta BM (2011) Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children's Oncology Group (POG 9404). Blood 118:874-883
13. Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui CH (1998) Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 338:499-505 (Pubitemid 28103133)
14. Lauer SJ, Shuster JJ, Mahoney DH Jr, Winick N, Toledano S, Munoz L, Kiefer G, Pullen JD, Steuber CP, Camitta BM (2001) A comparison of early intensive methotrexate/mercaptopurine with early intensive alternating combination chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: a pediatric oncology group phase III randomized trial. Leukemia 15:1038-1045 (Pubitemid 32717272)
15. Mahoney DH Jr, Shuster JJ, Nitschke R, Lauer SJ, Steuber CP, Winick N, Camitta B (1998) Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy-a pediatric oncology group study. J Clin Oncol 16:1712-1722
16. Whitehead VM, Vuchich MJ, Cooley LD, Lauer SJ, Mahoney DH, Shuster JJ, Payment C, Koch PA, Akabutu JJ, Bowen T, Kamen BA, Ravindranath Y, Emami A, Look AT, Beardsley GP, Pullen DJ, Camitta B (1998) Accumulation of methotrexate polyglutamates, ploidy and trisomies of both chromosomes 4 and 10 in lymphoblasts from children with B-progenitor cell acute lymphoblastic leukemia: a pediatric oncology group study. Leuk Lymphoma 31:507-519 (Pubitemid 29050592)
17. Chan H, Evans WE, Pratt CB (1977) Recovery from toxicity associated with high-dose methotrexate: prognostic factors. Cancer Treat Rep 61:797-804 (Pubitemid 8167605)
18. Von Hoff DD, Penta JS, Helman LJ, Slavik M (1977) Incidence of drug-related deaths secondary to high-dose methotrexate and citrovorum factor administration. Cancer Treat Rep 61:745-748 (Pubitemid 8156490)
19. Widemann BC, Adamson PC (2006) Understanding and managing methotrexate nephrotoxicity. Oncologist 11:694-703 (Pubitemid 43967624)
20. Gupta S, Antillon FA, Bonilla M, Fu L, Howard SC, Ribeiro RC, Sung L (2011) Treatment-related mortality in children with acute lymphoblastic leukemia in Central America. Cancer 117:4788-4795
21. Buchen S, Ngampolo D, Melton RG, Hasan C, Zoubek A, Henze G, Bode U, Fleischhack G (2005) Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure. Br J Cancer 92:480-487 (Pubitemid 40395528)
22. Relling MV, Fairclough D, Ayers D, Crom WR, Rodman JH, Pui CH, Evans WE (1994) Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol 12:1667-1672 (Pubitemid 24245003)
23. Evans WE, Pratt CB, Taylor RH, Barker LF, Crom WR (1979) Pharmacokinetic monitoring of high-dose methotrexate. Early recognition of high-risk patients. Cancer Chemother Pharmacol 3:161-166 (Pubitemid 10203329)
24. Crom WR, Evans WE (1992) Methotrexate. In: Evans WE, Schentag JJ, Jusko WJ (eds) Applied pharmacokinetics: principles of therapeutic drug monitoring. Applied Therapeutics, San Francisco, pp 1-42
25. Allegra CJ (1990) Antifolates. In: Chabner BA, Collins JM (eds) Cancer chemotherapy: principles and practice. Lippincott, Philadelphia, pp 110-153
26. Barredo JC, Synold TW, Laver J, Relling MV, Pui CH, Priest DG, Evans WE (1994) Differences in constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemia. Blood 84:564-569 (Pubitemid 24215957)
27. Rask C, Albertioni F, Bentzen SM, Schroeder H, Peterson C (1998) Clinical and pharmacokinetic risk factors for high-dose methotrexate-induced toxicity in children with acute lymphoblastic leukemia - a logistic regression analysis. Acta Oncol 37:277-284 (Pubitemid 28307853)
28. Masson E, Relling MV, Synold TW, Liu Q, Schuetz JD, Sandlund JT, Pui CH, Evans WE (1996) Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate. J Clin Invest 97:73-80
29. Wall AM, Gajjar A, Link A, Mahmoud H, Pui CH, Relling MV (2000) Individualized methotrexate dosing in children with relapsed acute lymphoblastic leukemia. Leukemia 14:221-225 (Pubitemid 30095374)
30. Mikkelsen TS, Sparreboom A, Cheng C, Zhou Y, Boyett JM, Raimondi SC, Panetta JC, Bowman WP, Sandlund JT, Pui CH, Relling MV, Evans WE (2011) Shortening infusion time for high-dose methotrexate alters antileukemic effects: a randomized prospective clinical trial. J Clin Oncol 29:1771-1778
31. Dombrowsky E, Jayaraman B, Narayan M, Barrett JS (2011) Evaluating performance of a decision support system to improve methotrexate pharmacotherapy in children and young adults with cancer. Ther Drug Monit 33:99-107
32. Aumente D, Buelga DS, Lukas JC, Gomez P, Torres A, Garcia MJ (2006) Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia. Clin Pharmacokinet 45:1227-1238 (Pubitemid 44904825)
33. Faltaos DW, Hulot JS, Urien S, Morel V, Kaloshi G, Fernandez C, Xuan KH, Leblond V, Lechat P (2006) Population pharmacokinetic study of methotrexate in patients with lymphoid malignancy. Cancer Chemother Pharmacol 58:626-633 (Pubitemid 44167388)
34. D'Argenio D, Schumitzky A (1990) ADAPT II user's guide. Biomedical Simulations Resource, Los Angeles
35. Evans WE, Stewart CF, Hutson PR, Cairnes DA, Bowman WP, Yee GC, Crom WR (1982) Disposition of intermediate-dose methotrexate in children with acute lymphocytic leukemia. Drug Intell Clin Pharm 16:839-842 (Pubitemid 13193011)
36. Crom WR, Glynn AM, Abromowitch M, Pui CH, Dodge R, Evans WE (1986) Use of the automatic interaction detector method to identify patient characteristics related to methotrexate clearance. Clin Pharmacol Ther 39:592-597 (Pubitemid 16113136)
37. Draper NR, Smith H (1998) Applied regression analysis. Wiley, New York
38. Pui CH, Simone JV, Hancock ML, Evans WE, Williams DL, Bowman WP, Dahl GV, Dodge RK, Ochs J, Abromowitch M et al (1992) Impact of three methods of treatment intensification on acute lymphoblastic leukemia in children: long-term results of St Jude total therapy study X. Leukemia 6:150-157
39. Lopez-Lopez E, Martin-Guerrero I, Ballesteros J, Pinan MA, Garcia-Miguel P, Navajas A, Garcia-Orad A (2011) Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 57:612-619
40. D'Angelo V, Ramaglia M, Iannotta A, Crisci S, Indolfi P, Francese M, Affinita MC, Pecoraro G, Napolitano A, Fusco C, Oreste M, Indolfi C, Casale F (2011) Methotrexate toxicity and efficacy during the consolidation phase in paediatric acute lymphoblastic leukaemia and MTHFR polymorphisms as pharmacogenetic determinants. Cancer Chemother Pharmacol 68:1339-1346
41. Woessmann W, Seidemann K, Mann G, Zimmermann M, Burkhardt B, Oschlies I, Ludwig WD, Klingebiel T, Graf N, Gruhn B, Juergens H, Niggli F, Parwaresch R, Gadner H, Riehm H, Schrappe M, Reiter A (2005) The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM group study NHL-BFM95. Blood 105:948-958 (Pubitemid 40170860)
42. Stoller RG, Hande KR, Jacobs SA, Rosenberg SA, Chabner BA (1977) Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med 297:630-634 (Pubitemid 8200049)